AG2R LA Mondiale Gestion D Actifs Takes Position in Thermo Fisher Scientific Inc. $TMO

AG2R LA Mondiale Gestion D Actifs bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 14,155 shares of the medical research company’s stock, valued at approximately $7,044,000.

A number of other hedge funds have also bought and sold shares of TMO. GAMMA Investing LLC grew its stake in Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. Nuveen LLC acquired a new position in Thermo Fisher Scientific in the first quarter worth about $532,360,000. Sarasin & Partners LLP acquired a new position in Thermo Fisher Scientific in the first quarter worth about $242,991,000. Two Sigma Advisers LP lifted its holdings in Thermo Fisher Scientific by 81.6% in the fourth quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company’s stock worth $485,479,000 after acquiring an additional 419,200 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Thermo Fisher Scientific in the fourth quarter worth about $195,049,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Up 3.1%

Thermo Fisher Scientific stock opened at $491.29 on Friday. The company has a market cap of $185.52 billion, a P/E ratio of 28.41, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The company has a fifty day simple moving average of $465.84 and a 200 day simple moving average of $452.06. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the firm posted $5.37 EPS. Thermo Fisher Scientific’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMO. Barclays raised shares of Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $490.00 to $550.00 in a report on Thursday. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. William Blair assumed coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating on the stock. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Finally, HSBC reissued a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.